FDA rejects 2 drugs from 503B bulks list

Two medications, ephedrine sulfate and hydroxychloroquine sulfate, were denied inclusion on the FDA’s 503B bulks list, the agency said Aug. 21. 

Advertisement

Outsourcing facilities are only allowed to compound drugs with five bulk substances — diphenylcyclopropenone, glycolic acid, quinacrine hydrochloride, squaric acid dibutyl ester and trichloroacetic acid — for specific uses, such as topical or oral use. 

The FDA has evaluated and blocked 20 other solutions from joining the list, according to documents.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.